Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B1 | P15538 | 15/20 | 0.56 |
| ▸ | CYP11B2 | P19099 | 15/20 | 0.56 |
| ▸ | CYP19A1 | P11511 | 3/20 | 0.46 |
| ▸ | CTBP2 | P56545 | 1/20 | 0.41 |
| ▸ | FNTA | P49354 | 1/20 | 0.40 |
| ▸ | FNTB | P49356 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7501151 | 0.81 | RAB9A (0.46) | CYP11B1CYP11B2 | |
| SCHEMBL5088981 | 0.78 | CYP11B1 (0.50) | CYP11B1CYP11B2CYP19A1FNTAFNTB | |
| SCHEMBL10445199 | 0.74 | PREP (0.41) | CYP11B1CYP11B2FNTAFNTBGAA | |
| SCHEMBL3824590 | 0.72 | CYP11B1 (1.00) | CYP11B1CYP11B2CYP19A1FNTAFNTB | |
| SCHEMBL2649430 | 0.71 | CTBP2 (0.56) | CYP11B1CYP11B2CTBP2 | |
| SCHEMBL6708657 | 0.70 | CYP11B1 (0.72) | CYP11B1CYP11B2CYP19A1FNTAFNTB | |
| SCHEMBL7572062 | 0.70 | CYP11B1 (0.47) | CYP11B1CYP11B2CYP19A1FNTAFNTB | |
| SCHEMBL15201808 | 0.70 | CYP11B2 (0.43) | CYP11B1CYP11B2CYP19A1 | |
| SCHEMBL8916921 | 0.70 | PREP (0.36) | CYP11B1CYP11B2 | |
| SCHEMBL6738597 | 0.70 | GSK3B (0.63) | CTBP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020156113-A1 | Farnesyl transferase inhibitors; anticancer agents | LES LABORATOIRES SERVIER (FR) | 2002-10-24 | — | — | US | disclosed |
| WO-2002057258-A1 | CYCLO`D!AZEPANE DERIVATIVES WHICH ARE USED AS FARNESYLTRANSFERASE INHIBITORS AND METHOD FOR THE PREPARATION THEREOF | LES LABORATOIRES SERVIER (FR) | 2002-07-25 | — | — | WO | disclosed |
| WO-2002057257-A1 | CYCLO`C!AZEPANE DERIVATIVES WHICH ARE USED AS FARNESYLTRANSFERASE INHIBITORS AND METHOD FOR THE PREPARATION THEREFOR | LES LABORATOIRES SERVIER (FR) | 2002-07-25 | — | — | WO | disclosed |
| EP-1225170-A2 | Cycloheptene compounds, process for their preparation and pharmaceutical compositions containing them | Les Laboratoires Servier S.A. (FR) | 2002-07-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020156113-A1 | Farnesyl transferase inhibitors; anticancer agents | COASY, FNTA, FNTB | CYP11B1 147/4885CYP11B2 399/4885CYP19A1 537/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.